Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Marek Borský"'
Autor:
Martin Stork, Eva Ondrouskova, Michaela Bohunova, Ivanna Boichuk, Dominik Fric, Zdenek Adam, Marta Krejci, Viera Sandecka, Zdenka Knechtova, Lenka Radova, Zuzana Jelinkova, Tatana Adlerova, Milan Krticka, Vladimir Nekuda, Marek Borsky, Sabina Sevcikova, Marie Jarosova, Ludek Pour
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-3 (2024)
Externí odkaz:
https://doaj.org/article/5aea7f2816d842e89d6116072aa074df
Autor:
Anežka Kvetková, Jitka Rychlíčková, Eduard Cmunt, Tomáš Jurček, Regina Demlová, Lukáš Semerád, Jiří Mayer, Kateřina Machová Poláková, Radka Štěpánová, Daniela Žáčková, Ivana Ježíšková, Edgar Faber, Michal Karas, Ondřej Wiewiorka, Petra Čičátková, Jiřina Procházková, Tomáš Horňák, Marek Borský, Lukas Stejskal, Petra Bělohlávková, O. Černá, Adam Svobodník, Hana Klamova
Publikováno v:
Blood. 138:3606-3606
Background. Treatment-free remission (TFR) has become a new treatment goal for chronic myeloid leukemia (CML) patients. However, usually abrupt tyrosine kinase inhibitors (TKIs) therapy discontinuation has been successful only in about half of eligib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e988edf24f9c19191d0a87c72eabc49e
https://doi.org/10.1182/blood-2021-146221
https://doi.org/10.1182/blood-2021-146221
Autor:
Dana Dvořáková, Martina Havelková, Irena Koutná, David Potěšil, Stanislav Stejskal, Filip Rázga, Pavel Šimara, Jiří Mayer, Zbyněk Zdráhal, Marek Borský, Zdeněk Ráčil
Publikováno v:
Analytical Letters. 47:944-957
Imatinib mesylate is a standard first-line therapy for patients with chronic myelogenous leukemia. However, there is still a significant proportion of these patients who reflect sub-optimal responses or fail imatinib therapy. Knowledge of the distrib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f192e2ab6f2f8697baa5a2fb205e7f5e
https://doi.org/10.1080/00032719.2013.860538
https://doi.org/10.1080/00032719.2013.860538
Autor:
Martin Trbušek, PrashantKumar Khirsariya, Yvona Brychtová, Marek Borský, Kamil Paruch, Miroslav Boudny
Publikováno v:
HemaSphere. 3:132
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a636a2314ffa5e25cffd70154219ccc
https://doi.org/10.1097/01.hs9.0000559656.22791.2d
https://doi.org/10.1097/01.hs9.0000559656.22791.2d
Autor:
Lucie Poppova, Sarka Pavlova, Beatriz Gonzalez, Jana Kotaskova, Karla Plevova, Gabrijela Dumbovic, Pavlina Janovska, Vojtech Bystry, Anna Panovska, Lucie Bezdekova, Stanislava Maslejova, Yvona Brychtova, Michael Doubek, Marcela Krzyzankova, Marek Borsky, Jiri Mayer, Vitezslav Bryja, Sergio Alonso, Sarka Pospisilova
Publikováno v:
Epigenetics, Vol 17, Iss 12, Pp 1628-1635 (2022)
Genome methylation profiles define naïve-like (n-CLL), memory-like (m-CLL), and intermediate (i-CLL) subsets of chronic lymphocytic leukaemia (CLL). The profiles can be easily determined by the analysis of the five-CpG signature. m-CLL, i-CLL, and n
Externí odkaz:
https://doaj.org/article/2ac6200ffdb247bbae9278ab0e3327a5
Autor:
Jiří Mayer, Šárka Pospíšilová, Jan Oppelt, Marek Mráz, Marek Borský, Kateřina Musilová, Gabriela Pavlasova, Michael Doubek, Yvona Brychtová, Veronika Svobodová, Kateřina Amruz Černá, Eva Vojackova, Jitka Novotná, Václav Šeda
Publikováno v:
Cancer Research. 78:1012-1012
The hallmark of chronic lymphocytic leukemia (CLL) cells is their re-circulation between peripheral blood and immune niches to obtain pro-proliferative and pro-survival signals. CLL cells that have recently exited the immune niches to the peripheral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fcc3e6f6454efe7075253159e931aa5a
https://doi.org/10.1158/1538-7445.am2018-1012
https://doi.org/10.1158/1538-7445.am2018-1012
Autor:
Miroslav Boudny, Jana Zemanova, Prashant Khirsariya, Marek Borsky, Jan Verner, Jana Cerna, Alexandra Oltova, Vaclav Seda, Marek Mraz, Josef Jaros, Zuzana Jaskova, Michaela Spunarova, Yvona Brychtova, Karel Soucek, Stanislav Drapela, Marie Kasparkova, Jiri Mayer, Kamil Paruch, Martin Trbusek
Publikováno v:
Haematologica, Vol 104, Iss 12 (2019)
Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation
Externí odkaz:
https://doaj.org/article/e872ad7d936f40299c20d4bb02b9ef06
Autor:
Šárka Pospíšilová, Anna Panovská, Kateřina Burčková, Tomáš Loja, Michael Doubek, Olga Stehlíková, Yvona Brychtová, H. Francová Skuhrová, Jana Chovancová, Jiří Mayer, Marta Krejčí, B. Tichý, Marek Borský
Publikováno v:
International Journal of Laboratory Hematology
International Journal of Laboratory Hematology; Vol 36
International Journal of Laboratory Hematology; Vol 36
Introduction Minimal residual disease (MRD) detection has become increasingly important for the assessment of therapy response in chronic lymphocytic leukemia (CLL). However, current MRD analysis methods, both molecular genetic and flow cytometric, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a048e93ecccc491492e998afbd50f94